Aligos Therapeutics (ALGS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $4.86, -9.83% vs the prior close of $5.39.
- Volume 67.48K shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
ALGS slides 9.8% to $4.86, a 1-month low. Closed at $4.86, -9.83% vs the prior close of $5.39. Day range $4.86–$5.50, opened at $5.32.
ALGS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ALGS slides 9.8% to $4.86, a 1-month low
- Closed at $4.86, -9.83% vs the prior close of $5.39. Day range $4.86–$5.50, opened at $5.32.
- Volume was 67.48K shares, 0.8x its 50-day average of 79.52K.
- Price is -18.2% vs its 50-day average ($5.94) and -24.7% vs its 200-day average ($6.45).
- 52-week range $3.98–$13.69; today's close sits at 9% of that range, 64.5% below the 52-week high.
Oct 15, 2026 — ALGS jumps 3.1% to $5.39
- Closed at $5.39, +3.06% vs the prior close of $5.23. Day range $5.19–$5.41, opened at $5.40.
- Volume was 25.50K shares, 0.3x its 50-day average of 80.44K — lighter than usual.
- Price is -9.5% vs its 50-day average ($5.96) and -16.8% vs its 200-day average ($6.47).
- 52-week range $3.98–$13.69; today's close sits at 15% of that range, 60.6% below the 52-week high.
Oct 14, 2026 — ALGS slides 5.1% to $5.23
- Closed at $5.23, -5.08% vs the prior close of $5.51. Day range $5.21–$5.60, opened at $5.50.
- Volume was 60.60K shares, 0.7x its 50-day average of 80.86K.
- Price is -12.0% vs its 50-day average ($5.94) and -19.5% vs its 200-day average ($6.50).
- 52-week range $3.98–$13.69; today's close sits at 13% of that range, 61.8% below the 52-week high.
Oct 13, 2026 — ALGS dips 0.4% to $5.51
- Closed at $5.51, -0.36% vs the prior close of $5.53. Day range $5.20–$5.60, opened at $5.47.
- Volume was 34.00K shares, 0.4x its 50-day average of 82.88K — lighter than usual.
- Price is -7.1% vs its 50-day average ($5.93) and -15.5% vs its 200-day average ($6.52).
- 52-week range $3.98–$13.69; today's close sits at 16% of that range, 59.7% below the 52-week high.
Oct 12, 2026 — ALGS jumps 3.6% to $5.53
- Closed at $5.53, +3.56% vs the prior close of $5.34. Day range $5.30–$5.64, opened at $5.50.
- Volume was 57.30K shares, 0.7x its 50-day average of 82.71K.
- Price is -6.5% vs its 50-day average ($5.92) and -15.5% vs its 200-day average ($6.55).
- 52-week range $3.98–$13.69; today's close sits at 16% of that range, 59.6% below the 52-week high.
Oct 9, 2026 — ALGS rises 0.6% to $5.34
- Closed at $5.34, +0.56% vs the prior close of $5.31. Day range $5.27–$5.44, opened at $5.27.
- Volume was 8.90K shares, 0.1x its 50-day average of 84.51K — lighter than usual.
- Price is -9.3% vs its 50-day average ($5.89) and -18.7% vs its 200-day average ($6.57).
- 52-week range $3.98–$13.69; today's close sits at 14% of that range, 61.0% below the 52-week high.
Oct 8, 2026 — ALGS ends flat (-0.2%) to $5.31, 4 down days in a row
- Closed at $5.31, -0.19% vs the prior close of $5.32. Day range $5.08–$5.53, opened at $5.25.
- Volume was 37.40K shares, 0.4x its 50-day average of 84.69K — lighter than usual.
- Price is -9.5% vs its 50-day average ($5.87) and -19.5% vs its 200-day average ($6.59).
- 52-week range $3.98–$13.69; today's close sits at 14% of that range, 61.2% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — ALGS dips 1.1% to $5.32, 3 down days in a row
- Closed at $5.32, -1.12% vs the prior close of $5.38. Day range $5.23–$5.53, opened at $5.33.
- Volume was 19.40K shares, 0.2x its 50-day average of 86.05K — lighter than usual.
- Price is -9.0% vs its 50-day average ($5.85) and -19.7% vs its 200-day average ($6.62).
- 52-week range $3.98–$13.69; today's close sits at 14% of that range, 61.1% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — ALGS dips 0.4% to $5.38
- Closed at $5.38, -0.37% vs the prior close of $5.40. Day range $5.31–$5.53, opened at $5.46.
- Volume was 12.80K shares, 0.1x its 50-day average of 90.05K — lighter than usual.
- Price is -7.7% vs its 50-day average ($5.83) and -19.1% vs its 200-day average ($6.65).
- 52-week range $3.98–$13.69; today's close sits at 14% of that range, 60.7% below the 52-week high.
Oct 5, 2026 — ALGS dips 2.5% to $5.40
- Closed at $5.40, -2.53% vs the prior close of $5.54. Day range $5.35–$5.65, opened at $5.57.
- Volume was 48.60K shares, 0.5x its 50-day average of 93.14K — lighter than usual.
- Price is -6.9% vs its 50-day average ($5.80) and -19.1% vs its 200-day average ($6.67).
- 52-week range $3.98–$13.69; today's close sits at 15% of that range, 60.6% below the 52-week high.
Oct 2, 2026 — ALGS rises 0.7% to $5.54
- Closed at $5.54, +0.73% vs the prior close of $5.50. Day range $5.37–$5.72, opened at $5.58.
- Volume was 29.00K shares, 0.3x its 50-day average of 95.51K — lighter than usual.
- Price is -4.1% vs its 50-day average ($5.77) and -17.4% vs its 200-day average ($6.70).
- 52-week range $3.98–$13.69; today's close sits at 16% of that range, 59.5% below the 52-week high.
ALGS latest news & SEC filings
Every SEC filing by or about ALGS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 15, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Aug 6, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $965.00K) (-100.0% vs Jun 30, 2025)
- Net income: -$1.50M (prior year -$15.86M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.14 (prior year -$1.53) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 29, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 26, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Jun 24, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ALGS
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 5, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.16% (largest 9.8%).
- Liquidity: about 44.80K shares (≈$217.72K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $4.86 vs a range of $3.98–$13.69 (9% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 15, 2026; 10-Q Aug 6, 2026; 8-K Aug 6, 2026.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ALGS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 5.32 | 5.50 | 4.86 | 4.86 | 67.48K |
| Oct 15, 2026 | 5.40 | 5.41 | 5.19 | 5.39 | 25.50K |
| Oct 14, 2026 | 5.50 | 5.60 | 5.21 | 5.23 | 60.60K |
| Oct 13, 2026 | 5.47 | 5.60 | 5.20 | 5.51 | 34.00K |
| Oct 12, 2026 | 5.50 | 5.64 | 5.30 | 5.53 | 57.30K |
| Oct 9, 2026 | 5.27 | 5.44 | 5.27 | 5.34 | 8.90K |
| Oct 8, 2026 | 5.25 | 5.53 | 5.08 | 5.31 | 37.40K |
| Oct 7, 2026 | 5.33 | 5.53 | 5.23 | 5.32 | 19.40K |
| Oct 6, 2026 | 5.46 | 5.53 | 5.31 | 5.38 | 12.80K |
| Oct 5, 2026 | 5.57 | 5.65 | 5.35 | 5.40 | 48.60K |
| Oct 2, 2026 | 5.58 | 5.72 | 5.37 | 5.54 | 29.00K |
| Oct 1, 2026 | 5.69 | 5.74 | 5.37 | 5.50 | 28.30K |
| Sep 30, 2026 | 5.65 | 5.80 | 5.54 | 5.63 | 35.30K |
| Sep 29, 2026 | 5.53 | 5.68 | 5.40 | 5.62 | 11.50K |
| Sep 28, 2026 | 5.38 | 5.54 | 5.18 | 5.54 | 79.50K |
| Sep 25, 2026 | 5.70 | 5.76 | 5.47 | 5.51 | 45.00K |
| Sep 24, 2026 | 5.55 | 5.70 | 5.27 | 5.55 | 59.60K |
| Sep 23, 2026 | 5.72 | 5.94 | 5.45 | 5.56 | 35.10K |
| Sep 22, 2026 | 5.57 | 6.30 | 5.22 | 5.68 | 75.70K |
| Sep 21, 2026 | 5.31 | 5.88 | 5.21 | 5.49 | 125.00K |
About Aligos Therapeutics
Aligos Therapeutics (ALGS) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SOUTH SAN FRANCISCO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1799448.
ALGS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Lawrence Blatt | President and CEO | Mar 11, 2026 |
| Margarita Chavez | Director | Jun 29, 2026 |
| Peter Hirth | Director | Jun 29, 2026 |
| Bridget A Martell | Director | Jun 29, 2026 |
| Carole Nuechterlein | Director | Jun 29, 2026 |
| Heather Preston | Director | Jun 29, 2026 |
| James Paul Scopa | Director | Jun 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Nikhil Aneja | Principal Accounting Officer | Mar 11, 2026 |
| Lawrence Blatt | President and CEO | Mar 11, 2026 |
| Lesley Ann Calhoun | See Remarks | Mar 11, 2026 |
| Julian A. Symons | See Remarks | Mar 11, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
ALGS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.19M | $-24.19M | -2.45 | $-82.50M |
| Dec 31, 2024 | $3.61M | $-131.21M | -20.94 | $-80.74M |
| Dec 31, 2023 | $6.19M | $-87.68M | -34.20 | $-79.00M |
| Dec 31, 2022 | $0 | $-96.05M | -2.25 | $-79.39M |
| Dec 31, 2021 | $0 | $-128.33M | — | $-115.66M |
Latest balance sheet: total assets $66.33M, total liabilities $34.44M, cash $30.38M (as of Jun 30, 2026).
ALGS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $5.51 |
| May 7, 2026 | 8-K Item 2.02 (results) | $6.03 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $6.66 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $7.10 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $8.04 |
| May 6, 2025 | 8-K Item 2.02 (results) | $4.58 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $10.41 |
| Nov 6, 2024 | 8-K Item 2.02 (results) | $9.35 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
| Mar 12, 2024 | 8-K Item 2.02 (results) | — |
| Nov 2, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ALGS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.